Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 02 Jan 2019 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
- 02 Jan 2019 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2019.
- 16 Oct 2018 Status changed to completed.